Dietwiller, France

Estelle Trifilieff

USPTO Granted Patents = 4 

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 61(Granted Patents)


Location History:

  • Basel, CH (2013)
  • Dietwiller, FR (2013 - 2022)

Company Filing History:


Years Active: 2013-2022

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Estelle Trifilieff: Innovator in Myostatin Antagonists

Introduction

Estelle Trifilieff is a prominent inventor based in Dietwiller, France. She has made significant contributions to the field of biotechnology, particularly in the development of myostatin antagonists for medical applications. With a total of 4 patents to her name, her work focuses on innovative treatments for conditions such as cancer cachexia.

Latest Patents

One of her latest patents is titled "Uses of myostatin antagonists, combinations containing them and uses thereof." This invention relates to myostatin antagonists that are beneficial in treating cancer cachexia, especially in patients undergoing chemotherapeutic treatment. The myostatin antagonist bimagrumab has shown promise in reducing body weight loss associated with cancer cachexia. Additionally, her patent includes combinations of a myostatin antagonist and an mTOR inhibitor aimed at treating cancer cachexia by managing body weight changes and addressing age-related conditions.

Another significant patent is "Method for treating metabolic disorders by administration of an anti-ActRIIB antibody." This invention involves compositions that include anti-ActRIIB antibodies, which are designed to increase brown fat in vertebrates, including humans, without adversely affecting hematological parameters.

Career Highlights

Estelle Trifilieff is currently associated with Novartis AG, a leading global healthcare company. Her work at Novartis has allowed her to focus on groundbreaking research and development in the field of metabolic disorders and cancer treatment.

Collaborations

Throughout her career, Estelle has collaborated with notable colleagues, including Catrin Berger and Tanja Herrmann. These collaborations have further enhanced her research and contributed to the advancement of innovative treatments.

Conclusion

Estelle Trifilieff is a trailblazer in the field of biotechnology, with her patents paving the way for new treatments for cancer cachexia and metabolic disorders. Her contributions continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…